Liver Injury Associated with the Selective Progesterone Modulator Ulipristal.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Björnsson, Einar SIssue Date
2020-10-09
Metadata
Show full item recordCitation
Björnsson ES. Liver Injury Associated with the Selective Progesterone Modulator Ulipristal. Drug Saf. 2020 Dec;43(12):1201-1204. doi: 10.1007/s40264-020-01004-4.Additional Links
https://link.springer.com/article/10.1007%2Fs40264-020-01004-4ae974a485f413a2113503eed53cd6c53
10.1007/s40264-020-01004-4
Scopus Count
Collections
Related articles
- The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor.
- Authors: Small B, Millard CEF, Kisanga EP, Burman A, Anam A, Flannery C, Al-Hendy A, Whirledge S
- Issue date: 2020 Mar 1
- An Evaluation of Postmarketing Reports of Serious Idiosyncratic Liver Injury Associated with Ulipristal Acetate for the Treatment of Uterine Fibroids.
- Authors: Kang S, Brinker A, Jones SC, Dimick-Santos L, Avigan MI
- Issue date: 2020 Dec
- Treatment of endometriosis-related chronic pelvic pain with Ulipristal Acetate and associated endometrial changes.
- Authors: Bressler LH, Bernardi LA, Snyder MA, Wei JJ, Bulun S
- Issue date: 2017 Dec
- Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report.
- Authors: Levy G, Elkas J, Armstrong AY, Nieman LK
- Issue date: 2016 Mar-Apr
- Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
- Authors: Donnez J, Donnez O, Dolmans MM
- Issue date: 2016 Dec